Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | Director | May 18, 2023 | May 22, 2023 |
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Director | December 16, 2025 | December 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date May 18, 2023 · Filed May 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-05-18 transaction · row 1
1 source rowRow 1 · 2023-05-18 · Gift · Disposed 3,876 · Balance 0 F1: Shares were transferred from direct ownership to ownership under the Skyler Bach Family Limited Partnership, LLP, upon vesting of previously awarded restricted stock units. |
| Common StockSEC Table I · non-derivative | Indirectby Partnership | 63,348 |
Reported balance
After 2023-05-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-05-18 · Gift · Acquired 3,876 · Balance 63,348 F1: Shares were transferred from direct ownership to ownership under the Skyler Bach Family Limited Partnership, LLP, upon vesting of previously awarded restricted stock units. F2: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 40,000 |
Reported balance
Holding disclosure · report date 2023-05-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 40,000 F3: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were transferred from direct ownership to ownership under the Skyler Bach Family Limited Partnership, LLP, upon vesting of previously awarded restricted stock units.
F2: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares.
F3: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
SAB Biotherapeutics, Inc.
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2035-12-16 | Direct | 150,000 |
Reported balance
After 2025-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-16 · Grant · Acquired 150,000 · Balance 150,000 F1: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.
F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Applied Therapeutics, Inc.
Report date February 03, 2026 · Filed February 03, 2026
Section 16 reporting ended · disclosed 2026-02-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-02-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-03 · Disposition to issuer · Disposed 22,500 · Balance 42,500 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. Row 2 · 2026-02-03 · Other · Disposed 42,500 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). F3: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-03 · Disposition to issuer · Disposed 20,460 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-03 · Disposition to issuer · Disposed 10,230 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-03 · Disposition to issuer · Disposed 16,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-03 · Disposition to issuer · Disposed 16,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.
F3: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2018 Filed Feb 15, 2019 21:59 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 4,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-19-000029 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,607 F1 · shares: Shares were transferred from direct ownership to ownership under the Skyler Bach Family Limited Partnership, LLP, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 31, 2018 Filed Jun 5, 2018 00:02 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 3,616 | $0.00 | $3.62 |
DisclosureSEC source: 0001093557-18-000115 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,169 F1 · security: Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. commom stock upon settlement. F2 · shares: The RSU Award was granted on May 31, 2018 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2019 Annual Meeting. F3 · balance_after: Represents 8,169 restricted stock units, 4,553 of which were granted on June 1, 2017 and shall vest on June 1, 2018 and 3,616 of which were granted on May 31, 2018 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2019 Annual Meeting. Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0001093557-18-000094 · edgardoc.xml · derivative · entry 5 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 25,806 Underlying: Common Stock · 30,000 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 30,000 | $88.00 | $2,640,000.00 |
DisclosureSEC source: 0001093557-18-000094 · edgardoc.xml · nonDerivative · entry 2 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 22,257 F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 30,000 | $4.58 | $137,400.00 |
DisclosureSEC source: 0001093557-18-000094 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 52,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2018 Filed May 10, 2018 00:22 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 31,464 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001093557-18-000086 · edgardoc.xml · derivative · entry 5 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 0 Underlying: Common Stock · 31,464 shares Expires 2018-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
| May 08, 2018 Filed May 10, 2018 00:22 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 31,464 | $85.11 | $2,678,023.75 |
DisclosureSEC source: 0001093557-18-000086 · edgardoc.xml · nonDerivative · entry 2 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 22,257 F2 · price: This transaction was executed in multiple trades at prices ranging from $84.85 to $85.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
| May 08, 2018 Filed May 10, 2018 00:22 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 31,464 | $7.63 | $240,070.32 |
DisclosureSEC source: 0001093557-18-000086 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 53,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:50 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 4,553 | $0.00 | $4.55 |
DisclosureSEC source: 0001093557-17-000149 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,553 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 23:28 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 31,890 | $78.13 Strike: $7.31 | $2,491,572.08 |
DisclosureSEC source: 0001093557-17-000050 · edgardoc.xml · derivative · entry 5 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 0 Underlying: Common Stock · 31,890 shares Expires 2017-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 23:28 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 31,890 | $78.13 | $2,491,572.08 |
DisclosureSEC source: 0001093557-17-000050 · edgardoc.xml · nonDerivative · entry 2 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 17,246 F2 · price: This transaction was executed in multiple trades at prices ranging from $78.00 to $78.28. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 23:28 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 31,890 | $7.31 | $233,115.90 |
DisclosureSEC source: 0001093557-17-000050 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 49,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
| September 12, 2016 Filed Sep 15, 2016 00:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 10,000 | $93.00 | $930,000.00 |
DisclosureSEC source: 0001093557-16-000703 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Daughter Disclosed balance after: 0 F1 · ownership.nature: Shares are held by Jennifer Skyler Living Trust, with respect to which the Reporting Person is a trustee. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:51 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 25,000 | $94.07 | $2,351,787.50 |
DisclosureSEC source: 0001093557-16-000699 · edgardoc.xml · nonDerivative · entry 1 SKYLER JAY S · CIK 0001236386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Partnership Disclosed balance after: 17,246 F1 · price: This transaction was executed in multiple trades at prices ranging from $93.68 to $95.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.